OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
LIVONIA, Mich., Aug. 07, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management is presenting at the Canaccord Genuity Growth Conference 2017, taking place August 9-10 in Boston, Massachusetts.
| Canaccord Genuity Growth Conference 2017 | |
| Date: | Wednesday, August 9 |
| Time: | 2:30pm Eastern Time |
| Presenter: | Lee Golden, MD, Chief Medical Officer |
| Location: | InterContinental Boston, Paris Room |
| Webcast: | http://wsw.com/webcast/canaccord26/gemp |
A webcast replay will be available on the News & Events section of the Gemphire website for all interested parties following the presentation and will be archived and available for 90 days. The slide presentation used during the conference will be posted to the Gemphire corporate website on August 9.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has initiated 3 clinical trials for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH to initiate in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734) 245-1700
